Opthea Past Earnings Performance

Past criteria checks 0/6

Opthea's earnings have been declining at an average annual rate of -52.4%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been growing at an average rate of 17.2% per year.

Key information

-52.4%

Earnings growth rate

-41.1%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate17.2%
Return on equityn/a
Net Margin-41,391.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Jul 21
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Mar 24
Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Oct 12
This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Mar 01
We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?

Dec 13
What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?

Revenue & Expenses Breakdown

How Opthea makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:OPT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-16219145
30 Sep 230-15224134
30 Jun 230-14328122
31 Mar 230-13728115
31 Dec 220-13227108
30 Sep 220-1132393
30 Jun 220-931879
31 Mar 220-751761
31 Dec 210-571644
30 Sep 210-511435
30 Jun 210-451326
31 Mar 210-391123
31 Dec 200-31719
30 Sep 200-21616
30 Jun 200-11512
31 Mar 200-10412
31 Dec 190-12416
30 Sep 190-13418
30 Jun 190-15422
31 Mar 190-13322
31 Dec 180-12322
30 Sep 180-12320
30 Jun 180-13318
31 Mar 180-12414
31 Dec 170-12410
30 Sep 170-847
30 Jun 170-544
31 Mar 170-544
31 Dec 160-534
30 Sep 160-533
30 Jun 160-533
31 Mar 160-433
31 Dec 150-333
30 Sep 150-323
30 Jun 150-434
31 Mar 151-424
31 Dec 141-424
30 Sep 141-434
30 Jun 141-433
31 Mar 141-333
31 Dec 131-233
30 Sep 131-343

Quality Earnings: OPT is currently unprofitable.

Growing Profit Margin: OPT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OPT is unprofitable, and losses have increased over the past 5 years at a rate of 52.4% per year.

Accelerating Growth: Unable to compare OPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).


Return on Equity

High ROE: OPT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.